Evaluation of FCE 22101 in experimental meningitis caused by Escherichia coli and Streptococcus pneumoniae.
FCE 22101 is a new penem antibiotic with a spectrum of activity suggesting a possible role in the empirical treatment of meningitis. It appears to achieve a mean reduction in bacterial titre in CSF comparable with currently accepted agents for both pneumococcal and Escherichia coli meningitis. Its efficacy may, however, be variable. It does not achieve CSF level/MIC ratios as favourable as imipenem for the pathogens studied. Further studies are necessary to determine its role, if any, in this disease.
Dworkin
R J
RJ
Department of Medicine, University of California, San Francisco.
Tureen
J H
JH
Kennedy
S L
SL
Sachdeva
M
M
Sande
M A
MA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000627:therapeutic use*; D001770:Blood Bactericidal Activity; D015780:Carbapenems; D002443:Ceftriaxone / Q000097:blood / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D015378:Imipenem / Q000097:blood / Q000627:therapeutic use; D008581:Meningitis / Q000188:drug therapy* / Q000382:microbiology; D008586:Meningitis, Pneumococcal / Q000188:drug therapy* / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000097:blood / Q000627:therapeutic use; D011817:Rabbits
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D010406:Penicillins; D015378:Imipenem; D002443:Ceftriaxone; C040033:ritipenem